ASTRO 2025: Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial – UroToday

ASTRO 2025: Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial  UroTodayRadiopharmaceutical added to stereotactic radiation can delay prostate cancer progression  Medical XpressNew therapy delays progression of recurrent prostate cancer  Medical Xpress

ASTRO 2025: 177Lu-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer: Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial – UroToday

ASTRO 2025: 177Lu-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer: Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial  UroTodayRadiopharmaceutical added to stereotactic radiation can delay prostate cancer progression  Medical XpressNew therapy delays progression of recurrent prostate cancer  Medical Xpress